Savient Pharmaceuticals is a specialty biopharmaceutical company specializing in the development and commercialization of KRYSTEXXA (pegloticase) for treating chronic gout in adult patients refractory to conventional therapy. The company has exclusively licensed global rights to the technology related to KRYSTEXXA and its uses from Duke University and Mountain View Pharmaceuticals, Inc. Savient additionally manufactures and supplies Oxandrin (oxandrolone tablets, USP) CIII in the United States. For more information, visit the company’s Web site at www.savient.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: